

Rockville, MD 20855, 301-827-7571, e-mail: jgotthar@cvm.fda.gov.

**SUPPLEMENTARY INFORMATION:**

Oxytetracycline hydrochloride soluble powder, used in solution for skeletal marking of juvenile finfish by immersion as an aid in identification is a new animal drug under section 201(v) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(v)). As a new animal drug, oxytetracycline hydrochloride is subject to section 512 of the act (21 U.S.C. 360b), requiring that its uses be the subject of an approved NADA or supplemental NADA. Fish are a minor species under § 514.1(d)(1)(ii) (21 CFR 514.1(d)(1)(ii)).

The NRSP-7 Project, North Eastern Region, New York State College of Veterinary Medicine, Cornell University, Ithaca, NY 14850, has provided target animal safety, effectiveness, human food safety, and environmental data for use of oxytetracycline hydrochloride soluble powder for skeletal marking of fish by immersion. These data are contained in PMF 5667.

Under §§ 25.15(d) and 25.33(d)(4) (21 CFR 25.15(d) and 25.33(d)(4)), sponsors of NADAs and supplemental NADAs for drugs in minor species, including wildlife and endangered species, are categorically excluded from the requirement to prepare an environmental assessment or an environmental impact statement when the drug has been approved for use in another or the same species where similar animal management practices are used. The categorical exclusion applies unless, as defined in § 25.21 (21 CFR 25.21), extraordinary circumstances exist which indicate that the proposed action may significantly affect the quality of the human environment. Therefore, based upon information available, FDA agrees that when the application is submitted, the applicant may claim a categorical exclusion under § 25.33(d)(4) provided that the applicant can state that to the best of the applicant's knowledge, as in § 25.21, no extraordinary circumstances exist. It is assumed that the applicant has made a reasonable effort to determine that no extraordinary circumstances exist.

Sponsors of NADAs or supplemental NADAs may, without further authorization, reference the PMF 5667 to support approval of an application filed under § 514.1(d). An NADA or supplemental NADA must include, in addition to reference to the PMF, animal drug labeling and other information needed for approval, such as: Data supporting extrapolation from a major species in which the drug is currently

approved or authorized reference to such data; data concerning manufacturing methods, facilities, and controls; and information addressing potential environmental impacts of the manufacturing process. Persons desiring more information concerning PMF 5667 or requirements for approval of an NADA or supplement may contact Joan C. Gotthardt (see **FOR FURTHER INFORMATION CONTACT**).

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information provided in PMF 5667 to support approval of an application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Dated: June 27, 2002.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 02-17749 Filed 7-12-02; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Resources and Services Administration**

**New Annual "Low-Income" Levels for Various Health Professions and Nursing Programs Included in Titles VII and VIII of the Public Health Service Act**

**AGENCY:** Health Resources and Services Administration (HRSA), HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces the new "low-income" levels for various programs included in titles VII and VIII of the Public Health Service (PHS) Act, which use the U.S. Census Bureau "low income" levels to determine eligibility for program participation. The Department periodically publishes in the **Federal Register** low-income levels used to determine eligibility for grants and cooperative agreements to institutions providing training for (1) disadvantaged individuals, (2) individuals from a disadvantaged background, or (3) individuals from "low-income" families.

**SUPPLEMENTARY INFORMATION:** This notice announces increase in income levels intended for use in determining eligibility for participation in the following programs:

Advanced Education Nursing (section 811)

Allied Health Special Projects (section 755)

Basic Nurse Education and Practice (section 831)

Dental Public Health (section 768)

Faculty Loan Repayment and Minority Faculty Fellowship Program (section 738)

General and Pediatric Dentistry (section 747)

Health Administration Traineeships and Special Projects (section 769)

Health Careers Opportunity Program (section 739)

Loans to Disadvantaged Students (section 724)

Physician Assistant Training (section 747)

Primary Care Residency Training (section 747)

Public Health Traineeships (section 767)

Quentin N. Burdick Program for Rural Interdisciplinary Training (section 754)

Residency Training in Preventive Medicine (section 768)

Public Health Training Centers (section 766)

Nursing Workforce Diversity (section 821)

These programs generally award grants to accredited schools of medicine, osteopathic medicine, public health, dentistry, veterinary medicine, optometry, pharmacy, allied health, podiatric medicine, nursing, chiropractic, public or private nonprofit schools which offer graduate programs in behavioral health and mental health practice, and other public or private nonprofit health or education entities to assist the disadvantaged to enter and graduate from health professions and nursing schools. Some programs provide for the repayment of health professions or nursing education loans for disadvantaged students.

**Low-Income Levels**

The Secretary defines a "low-income" family for programs included in titles VII and VIII of the PHS Act as having an annual income that does not exceed 200 percent of the Department's poverty guidelines. The Department's poverty guidelines which were published in the **Federal Register** on Thursday, February 14, 2002, (67 FR 6931), are based on poverty thresholds published by the U.S. Census Bureau, adjusted annually for changes in the Consumer Price Index. The Secretary annually adjusts the low-income levels based on the Department's poverty guideline and makes them available to persons responsible for administering the applicable programs. The following income figures will be used for health professions and nursing grant

applications requesting FY 2003 funding.

Size of parent's family <sup>1</sup>	Income <sup>2</sup> level
1 .....	\$17,720
2 .....	23,880
3 .....	30,040
4 .....	36,200
5 .....	42,360
6 .....	48,520
7 .....	54,680
8 .....	60,840

<sup>1</sup> Includes only dependents on Federal Income tax forms.

<sup>2</sup> Adjusted gross income for calendar year 2001.

Dated: July 9, 2002.

**Elizabeth M. Duke,**

*Administrator.*

[FR Doc. 02-17751 Filed 7-12-02; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and the personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, RFA AA00-003 Alcohol Research Centers Applications.

*Date:* July 30, 2002.

*Time:* 1 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Willco Building, Suite 409, 6000 Executive Boulevard, Rockville, MD 20892, (Telephone Conference Call).

*Contact Person:* Eugene G. Hayunga, PhD, Chief, Extramural Project Review Branch, OSA, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Willco Building, Suite 409, 6000 Executive Boulevard, MSC 7003, Rockville, MD 20892-7003, 301-443-2860, [ehayunga@mail.nih.gov](mailto:ehayunga@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: July 8, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-17673 Filed 7-12-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting:

*Name of Committee:* National Cancer Institute Director's Consumer Liaison Group.

*Date:* July 29, 2002.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To debrief on May 2002 meeting and to get updates from the working group.

*Place:* 6116 Executive Blvd., Rockville, MD 20892, (Telephone Conference Call).

*Contact Person:* Elaine Lee, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institute, 6116 Executive Boulevard, Suite 300 C, Bethesda, MD 20892, 301/594-3194.

This notice is being published less than 15 days prior to the meeting due to scheduling conflicts.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: [deainfo.nci.nih.gov/advisory/dclg/dclg.htm](http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 3, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-17658 Filed 7-12-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Advisory Committee to the Director, National Cancer Institute, July 10, 2002, 1 p.m. to July 10, 2002 3 p.m. National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 31, Room 11A03, Bethesda, MD, 20892 which was published in the **Federal Register** on June 18, 2002, 67 FR41434.

This meeting is amended to change the meeting time to 2:30 p.m. to 4 p.m. The meeting is open to the public.

Dated: July 3, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-17659 Filed 7-12-02; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary & Alternative Medicine; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Center for Complementary and Alternative Medicine Special Emphasis Panel, July 8, 2002, 2 pm to July 8, 2002, 5 pm, 6707 Democracy Blvd., Bethesda, MD, 20892 which was published in the **Federal Register** on June 18, 2002, 67 FR 41435.

The meeting will be held July 9, 2002 from 2 pm to 5 pm, 6707 Democracy Blvd., Bethesda, Maryland (telephone conference call). The meeting is closed to the public.